These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 31597496)

  • 1. S-1 or gemcitabine adjuvant therapy in resected pancreatic cancer: a cost-effectiveness analysis based on the JASPAC-01 trial.
    Liao W; Huang J; Zhu G; Zhou J; Wen F; Zhang P; Zhou K; Wu Q; Wang X; Gou H; Li Q
    Expert Rev Pharmacoecon Outcomes Res; 2020 Feb; 20(1):133-138. PubMed ID: 31597496
    [No Abstract]   [Full Text] [Related]  

  • 2. Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01).
    Uesaka K; Boku N; Fukutomi A; Okamura Y; Konishi M; Matsumoto I; Kaneoka Y; Shimizu Y; Nakamori S; Sakamoto H; Morinaga S; Kainuma O; Imai K; Sata N; Hishinuma S; Ojima H; Yamaguchi R; Hirano S; Sudo T; Ohashi Y;
    Lancet; 2016 Jul; 388(10041):248-57. PubMed ID: 27265347
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness analysis of FOLFIRINOX vs gemcitabine with nab-paclitaxel as adjuvant treatment for resected pancreatic cancer in the United States based on PRODIGE-24 and APACT trials.
    Kharat AA; Nelson R; Au T; Biskupiak J
    J Manag Care Spec Pharm; 2021 Oct; 27(10):1367-1375. PubMed ID: 34595948
    [No Abstract]   [Full Text] [Related]  

  • 4. Cost-effectiveness analysis of gemcitabine, S-1 and gemcitabine plus S-1 for treatment of advanced pancreatic cancer based on GEST study.
    Zhou J; Zhao R; Wen F; Zhang P; Tang R; Du Z; He X; Zhang J; Li Q
    Med Oncol; 2015 Apr; 32(4):121. PubMed ID: 25788034
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness analysis of adjuvant chemotherapies in patients presenting with gastric cancer after D2 gastrectomy.
    Wu B; Li T; Cai J; Xu Y; Zhao G
    BMC Cancer; 2014 Dec; 14():984. PubMed ID: 25526802
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of adjuvant chemotherapy for curatively resected gastric cancer with S-1.
    Hisashige A; Sasako M; Nakajima T
    BMC Cancer; 2013 Oct; 13():443. PubMed ID: 24079752
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative Cost-Effectiveness of Gemcitabine and Cisplatin in Combination with S-1, Durvalumab, or Pembrolizumab as First-Line Triple Treatment for Advanced Biliary Tract Cancer.
    Kashiwa M; Maeda H
    J Gastrointest Cancer; 2024 Dec; 55(4):1569-1580. PubMed ID: 39172318
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Health-related quality of life of adjuvant chemotherapy with S-1 versus gemcitabine for resected pancreatic cancer: Results from a randomised phase III trial (JASPAC 01).
    Hagiwara Y; Ohashi Y; Uesaka K; Boku N; Fukutomi A; Okamura Y; Konishi M; Matsumoto I; Kaneoka Y; Shimizu Y; Nakamori S; Sakamoto H; Morinaga S; Kainuma O; Imai K; Sata N; Hishinuma S; Ojima H; Yamaguchi R; Hirano S; Sudo T;
    Eur J Cancer; 2018 Apr; 93():79-88. PubMed ID: 29477795
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Economic evaluation of first-line adjuvant chemotherapies for resectable gastric cancer patients in China.
    Tan C; Peng L; Zeng X; Li J; Wan X; Chen G; Yi L; Luo X; Zhao Z
    PLoS One; 2013; 8(12):e83396. PubMed ID: 24340099
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized clinical trial of adjuvant chemotherapy with S-1 versus gemcitabine after pancreatic cancer resection.
    Shimoda M; Kubota K; Shimizu T; Katoh M
    Br J Surg; 2015 Jun; 102(7):746-54. PubMed ID: 25833230
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The clinical effectiveness and cost-effectiveness of gemcitabine for metastatic breast cancer: a systematic review and economic evaluation.
    Takeda AL; Jones J; Loveman E; Tan SC; Clegg AJ
    Health Technol Assess; 2007 May; 11(19):iii, ix-xi, 1-62. PubMed ID: 17462169
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Cost-effectiveness analysis of chemotherapy with GEM or S-1 for patients with non-resectable pancreatic cancer].
    Kurihara T; Kobayashi M; Kogo M; Yoneyama K; Ito N; Sunaga T; Konishi K; Imawari M; Tobe T; Kiuchi Y
    Gan To Kagaku Ryoho; 2010 Apr; 37(4):659-64. PubMed ID: 20414022
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness analysis of gemcitabine plus cisplatin versus docetaxel, cisplatin and fluorouracil for induction chemotherapy of locoregionally advanced nasopharyngeal carcinoma.
    Wu Q; Liao W; Huang J; Zhang P; Zhang N; Li Q
    Oral Oncol; 2020 Apr; 103():104588. PubMed ID: 32070923
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical implication of peritoneal cytology in the pancreatic cancer patients who underwent curative resection followed by adjuvant gemcitabine or S-1 chemotherapy.
    Aoyama T; Katayama Y; Murakawa M; Shiozawa M; Morimoto M; Yamamoto N; Yoshikawa T; Rino Y; Masuda M; Morinaga S
    Hepatogastroenterology; 2015; 62(137):200-6. PubMed ID: 25911897
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness analysis of adjuvant treatment for resected pancreatic cancer in China based on the ESPAC-4 trial.
    Huang J; Liao W; Zhou J; Zhang P; Wen F; Wang X; Zhang M; Zhou K; Wu Q; Li Q
    Cancer Manag Res; 2018; 10():4065-4072. PubMed ID: 30323662
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Economic Evaluation for USA of Systemic Chemotherapies as First-Line Treatment of Metastatic Pancreatic Cancer.
    Gharaibeh M; McBride A; Alberts DS; Slack M; Erstad B; Alsaid N; Bootman JL; Abraham I
    Pharmacoeconomics; 2018 Oct; 36(10):1273-1284. PubMed ID: 29948964
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-Effectiveness of Nab-Paclitaxel and Gemcitabine Versus Gemcitabine Monotherapy for Patients with Unresectable Metastatic Pancreatic Cancer in Japan.
    Morimoto K; Moriwaki K; Kaneyasu T; Nakayama H; Shimozuma K
    Value Health Reg Issues; 2022 Mar; 28():54-60. PubMed ID: 34800832
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized phase III trial of adjuvant chemotherapy with gemcitabine versus S-1 in patients with resected pancreatic cancer: Japan Adjuvant Study Group of Pancreatic Cancer (JASPAC-01).
    Maeda A; Boku N; Fukutomi A; Kondo S; Kinoshita T; Nagino M; Uesaka K
    Jpn J Clin Oncol; 2008 Mar; 38(3):227-9. PubMed ID: 18272475
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of gemcitabine + cisplatin vs. gemcitabine monotherapy in advanced biliary tract cancer.
    Roth JA; Carlson JJ
    J Gastrointest Cancer; 2012 Jun; 43(2):215-23. PubMed ID: 21234709
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for advanced recurrent or refractory ovarian cancer: a systematic review and economic evaluation.
    Edwards SJ; Barton S; Thurgar E; Trevor N
    Health Technol Assess; 2015 Jan; 19(7):1-480. PubMed ID: 25626481
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.